Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Prostate Cancer Therapy: Supporting Strategies and Management Options
share announcement

Prostate Cancer Therapy: Supporting Strategies and Management Options

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 5645

Special Issue Editors

Dr. Ingmar Wolff

E-Mail Website
Guest Editor
Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany
Interests: urological oncology; urological surgery; robot-assisted surgery
Prof. Dr. Matthias May

E-Mail Website
Guest Editor
Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany
Interests: bladder cancer; prostate cancer; renal cell carcinoma; robot-assisted surgery; biomarker-based oncology studies; prognostic outcome models; translational research; multicenter projects in genitourinary oncology research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Prostate cancer (PCa) stands as one of the most prevalent cancers affecting men globally. As with any malignancy, early detection, pre-treatment preparation and prehabilitation, and effective disease management are paramount in determining favorable patient outcomes.

We are excited to announce our upcoming Special Issue, aiming to provide a comprehensive overview of the current landscape of PCa treatment. It will particularly focus on supportive measures and diverse management options, serving as a vital resource for researchers, practitioners and clinicians in this field.

Within this Special Issue, we have specific interest in articles that delve into supportive measures. These may include investigations into lifestyle modifications, dietary interventions, physical activity or exercise regimens, and risk reduction techniques that have the potential to mitigate the risk of progression or enhance therapeutic responses. We believe that an interdisciplinary approach involving not only urologists and oncologists, but also nutritionists, exercise physiologists and public health professionals is crucial in this endeavor. Moreover, we welcome contributions that address the latest advancements, challenges and emerging approaches in the field of PCa therapy aiming to prevent the progression of initially localized PCa to more advanced stages. This Special Issue will serve as a platform for the exchange of innovative ideas and the dissemination of critical research findings, ultimately promoting progress in the understanding and treatment of PCa.

To ensure that this Special Issue becomes a comprehensive and authoritative resource, we are inviting submissions of original research and reviews. We are eager to receive your contributions and await your insightful research on PCa therapy and supportive strategies. Your expertise and dedication are crucial in advancing our collective knowledge in this critical area of medicine. We sincerely appreciate your commitment to advancing PCa research and patient care. We are confident that your contributions will significantly enhance the value of this Special Issue for the medical community.

Dr. Ingmar Wolff
Prof. Dr. Matthias May
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • therapy
  • supporting strategies
  • management options
  • lifestyle modifications
  • dietary interventions
  • risk reduction techniques
  • prehabilitation
  • physical activity
  • interdisciplinary approach
  • cancer early detection strategies
  • rehabilitation
  • complications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

17 pages, 1188 KiB  
Article
Meeting Cancer Detection Benchmarks in MRI/Ultrasound Fusion Biopsy for Prostate Cancer: Insights from a Retrospective Analysis of Experienced Urologists
by Fabian Utzat, Stefanie Herrmann, Matthias May, Johannes Moersler, Ingmar Wolff, Johann Lermer, Mate Gregor, Katharina Fodor, Verena Groß, Anton Kravchuk, Thomas Elgeti, Stephan Degener and Christian Gilfrich
Cancers 2025, 17(2), 277; https://doi.org/10.3390/cancers17020277 - 16 Jan 2025
Viewed by 527
Abstract
Background: The relationship between case volume and clinical outcomes is well established for most urological procedures but remains underexplored in prostate ultrasound/MRI fusion biopsy (UMFB). UMFB aims to detect clinically significant prostate cancer (csPCa) by adhering to cancer detection benchmarks for PI-RADS lesions [...] Read more.
Background: The relationship between case volume and clinical outcomes is well established for most urological procedures but remains underexplored in prostate ultrasound/MRI fusion biopsy (UMFB). UMFB aims to detect clinically significant prostate cancer (csPCa) by adhering to cancer detection benchmarks for PI-RADS lesions identified via multiparametric MRI (mpMRI). These benchmarks, defined by Ahmed et al., include cumulative cancer detection rate (C-CDR) targets of >80% for PI-RADS 5, >50% for PI-RADS 4, and <20% for PI-RADS 1–3. Methods: This retrospective, single-center study analyzed the case volumes required for two experienced urologists (U1 and U2, each with >15 years of practice) to consistently achieve the Ahmed-defined C-CDR benchmarks for csPCa (ISUP grade ≥ 2) using UMFB. Both transrectal and transperineal approaches were included to enable comprehensive learning curve analysis. Data from 2017 to 2023 were reviewed, encompassing 157 UMFBs performed by U1 and 242 by U2, with a transrectal-to-perineal ratio of 7:3. Results: Both urologists achieved Ahmed-defined C-CDR targets from the outset. Over a median follow-up of 30 months, patients with initial PI-RADS 4 or 5 ratings and negative primary biopsies remained prostate cancer-free in 77% of cases for U1 and 91.2% for U2 (p = 0.152). Conclusions: This study demonstrates that experienced urologists can achieve high diagnostic accuracy and maintain patient safety immediately upon implementing UMFB, meeting established benchmarks without requiring additional procedural learning. Full article
(This article belongs to the Special Issue Prostate Cancer Therapy: Supporting Strategies and Management Options)
►▼ Show Figures

Figure 1

10 pages, 2221 KiB  
Article
Long-Term Follow-Up of Peritoneal Interposition Flap in Symptomatic Lymphocele Reduction following Robot-Assisted Radical Prostatectomy: Insights from the PIANOFORTE Trial
by Christopher Goßler, Matthias May, Steffen Weikert, Sebastian Lenart, Anton Ponholzer, Christina Dreissig, Gjoko Stojanoski, Isabel Anzinger, Josef Riester, Maximilian Burger, Christian Gilfrich, Roman Mayr and Johannes Bründl
Cancers 2024, 16(10), 1932; https://doi.org/10.3390/cancers16101932 - 19 May 2024
Viewed by 931
Abstract
The available randomised controlled trials (RCTs) assessing the influence of peritoneal interposition flaps (PIF) on the reduction of symptomatic lymphoceles (sLCs) post robot-assisted radical prostatectomy (RARP) do not constitute a sufficient follow-up (FU) to assess the long-term effects. The PIANOFORTE trial was the [...] Read more.
The available randomised controlled trials (RCTs) assessing the influence of peritoneal interposition flaps (PIF) on the reduction of symptomatic lymphoceles (sLCs) post robot-assisted radical prostatectomy (RARP) do not constitute a sufficient follow-up (FU) to assess the long-term effects. The PIANOFORTE trial was the first of these RCTs, showing no sLC reduction at the 3-month FU. Therefore, all 232 patients from the PIANOFORTE trial were invited for long-term FU. One hundred seventy-six patients (76%) presented themselves for FU and constituted the study group (SG). The median FU duration was 43 months. No significant differences in group allocation or LC endpoints at 90 days were observed between SG patients and patients not presenting themselves for the FU. During the FU period, four patients (2.3%) in the SG developed sLCs, and six patients (3.4%) developed asymptomatic lymphoceles (aLCs), which persisted in five patients (2.9%). There were no significant differences between PIF and non-PIF regarding sLC/aLC formation or persistence, newly developed complications, stress urinary incontinence or biochemical/clinical tumour recurrence. Therefore, this long-term FU confirms the primary outcomes of the PIANOFORTE trial that, while PIF does not impact complications or functionality, it does not reduce sLC/aLC rates. Furthermore, it shows the potential occurrence of LC after the third postoperative month. Full article
(This article belongs to the Special Issue Prostate Cancer Therapy: Supporting Strategies and Management Options)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

18 pages, 823 KiB  
Review
To Drink or Not to Drink? Investigating Alcohol’s Impact on Prostate Cancer Risk
by Aris Kaltsas, Michael Chrisofos, Evangelos N. Symeonidis, Athanasios Zachariou, Marios Stavropoulos, Zisis Kratiras, Ilias Giannakodimos, Asterios Symeonidis, Fotios Dimitriadis and Nikolaos Sofikitis
Cancers 2024, 16(20), 3453; https://doi.org/10.3390/cancers16203453 - 12 Oct 2024
Viewed by 2606
Abstract
Background/Objectives: Prostate cancer (PCa) is a significant global health issue. The relationship between alcohol consumption and PCa risk has been the subject of extensive research, yet findings remain inconsistent. This review aims to clarify the association between alcohol intake and PCa risk, its [...] Read more.
Background/Objectives: Prostate cancer (PCa) is a significant global health issue. The relationship between alcohol consumption and PCa risk has been the subject of extensive research, yet findings remain inconsistent. This review aims to clarify the association between alcohol intake and PCa risk, its aggressiveness, and the potential metabolic pathways involved in PCa onset. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed and MEDLINE, focusing on epidemiological studies, meta-analyses, cohort studies, and case–control studies. Studies evaluating alcohol consumption, prostate-specific antigen (PSA) levels, and PCa risk were included. The review also explored the roles of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in alcohol metabolism. Results: The analysis reveals a complex relationship between alcohol consumption and PCa. Heavy alcohol intake is associated with an increased risk of PCa, particularly more aggressive forms, and higher mortality rates. However, studies also show weak or no association between moderate alcohol consumption and PCa. The variability in findings may be attributed to differences in alcohol types, regional factors, and study methodologies. Conclusions: The link between alcohol consumption and PCa risk is multifaceted. While heavy drinking appears to increase the risk of aggressive PCa, the overall relationship remains unclear. Further research is needed to better understand these associations and inform public health recommendations and cancer prevention strategies. Full article
(This article belongs to the Special Issue Prostate Cancer Therapy: Supporting Strategies and Management Options)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

26 pages, 1853 KiB  
Systematic Review
The Effect of Resistance and/or Aerobic Training on Quality of Life, Fitness, and Body Composition in Prostate Cancer Patients—A Systematic Review and Meta-Analysis
by Shimon Kempin, Alexander Buchner, Sarah Frederike Brose, Nina Schmidt-Hegemann, Matthias May, Ingmar Wolff, Anton Kravchuk, Christian Stief, Sabine D. Brookman-May and Benazir Enzinger
Cancers 2024, 16(24), 4286; https://doi.org/10.3390/cancers16244286 - 23 Dec 2024
Viewed by 886
Abstract
Background: Prostate cancer (PC) and its treatment are often associated with side effects such as fatigue, muscle loss, and diminished quality of life (QoL). Physical exercise, particularly resistance training (RT) and aerobic training (AT), has been suggested as a strategy to mitigate [...] Read more.
Background: Prostate cancer (PC) and its treatment are often associated with side effects such as fatigue, muscle loss, and diminished quality of life (QoL). Physical exercise, particularly resistance training (RT) and aerobic training (AT), has been suggested as a strategy to mitigate these effects. However, the comparative efficacy of RT, AT, and combined RT/AT on QoL, body composition, physical fitness, and laboratory markers in PC patients is still insufficiently understood. Methods: Randomized controlled trials (RCTs) investigating structured RT, AT, or combined RT/AT programs in PC patients undergoing various treatments were included. The primary outcome was QoL, assessed using EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. Secondary outcomes included body composition, fitness, and laboratory parameters. The studies were sourced from PubMed, Embase, and CENTRAL through May 2024. The effect sizes were pooled using random-effects models, and the risk of bias was systematically assessed following the GRADE approach. Results: A total of 30 RCTs, encompassing 2216 PC patients, were analyzed. Combined RT/AT significantly improved QoL subdomains, including global health, and cognitive and sexual function, while reducing fatigue and urinary symptoms. RT alone improved body composition by increasing lean body mass and reducing body fat percentage. Both RT and combined RT/AT enhanced strength (chest and leg press) and VO2peak. No significant changes were observed in laboratory markers, such as PSA or lipid levels. The effects of isolated AT remain unclear due to limited data. Conclusions: RT and combined RT/AT significantly improve QoL, fitness, and body composition in PC patients, with no detectable effect on PSA or lipid levels. Further research is needed to elucidate the specific effects of AT and to investigate long-term outcomes. Full article
(This article belongs to the Special Issue Prostate Cancer Therapy: Supporting Strategies and Management Options)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop